A Comparison of the Haemostatic Effect of Vivostat<sup>®</sup> Patient-Derived Fibrin Sealant with Oxidised Cellulose (Surgicel<sup>®</sup>) in Multiple Surgical Procedures

<i>Aim:</i> To evaluate the haemostatic properties of Vivostat^® patient-derived fibrin sealant in a broad range of surgical procedures. <i>Method:</i> In a prospective, randomised, multicentre, clinical study, typical surgical wounds of 69 patients (cardiothoracic, general, obstetric and gynaecologic, and vascular), requiring intervention to control bleeding, were treated with either Vivostat-derived sealant (n = 35) or Surgicel^® (n = 34) as required and the time taken to arrest bleeding was assessed. <i>Results:</i> Compared with Surgicel, the mean time to haemostasis of Vivostat-derived sealant was significantly shorter (1.6 vs. 3.3 min, p < 0.0001) and more patients were successfully treated (i.e. no additional haemostatic measures required; 94 vs. 65%, p = 0.003). <i>Conclusion:</i> Vivostat-derived sealant is a more reliable and rapidly effective surgical haemostat than Surgicel.